Baseline demographic, disease and laboratory characteristics. Disease extent based on Montreal classification for ulcerative colitis.
| Characteristic . | Intervention (n = 10) . | Placebo (n = 10) . |
|---|---|---|
| Women,n(%) | 4 (40%) | 5 (50%) |
| Age, mean (SD) | 53.5 (9.3) | 48.0 (12.9) |
| Age category, n (%) | ||
| 18-30 | 0 (0) | 1 (10) |
| 30-50 | 3 (30) | 5 (50) |
| 50-70 | 7 (70) | 4 (40) |
| Smoking, n (%) | ||
| Current | 1 (10) | 1 (10) |
| Past | 5 (50) | 3 (30) |
| BMI (mean, SD) | 19.6 (7.0) | 26.4 (6.2) |
| Time since diagnosis, years (median, IQR) | 16 (2.8-20) | 16 (4.5-23.0) |
| Disease extent, n (%) | ||
| E1 | 1 (10) | 1 (10) |
| E2 | 8 (80) | 3 (30) |
| E3 | 1 (10) | 6 (60) |
| Disease severity at worst, n (%) | ||
| Mild | 1 (10) | 1 (10) |
| Mod | 9 (90) | 7 (70) |
| Severe | 0 (0) | 2 (20) |
| Previous IMM,n(%) | 2 (20) | 3 (30) |
| Previous biologic,n(%) | 0 (0) | 0 (0) |
| Steroid use in last year,n(%) | 1 (10) | 2 (20) |
| Previous steroid use,n(%) | 8 (80) | 6 (60) |
| Severity of inflammation at last endoscopy, n (%) | ||
| Nil | 2 (20) | 3 (30) |
| Mild | 2 (20) | 5 (50) |
| Mod | 6 (60) | 2 (20) |
| Severe | 0 (0) | 0 (0) |
| Baseline SCCAI score (median, IQR) | 2.0 (2.0-2.0) | 2.0 (2.0-2.0) |
| Baseline SIBDQ (median, IQR) | 59.0 (52.8-64.5) | 59.50 (55.8-64.0) |
| Baseline fCal, ug/g (median, IQR) | 32.0 (29.0-38.8) | 33.0 (28.8-64.8) |
| Baseline CRP, mg/L (median, IQR) | 1.0 (1.0-8.0) | 1.0 (1.0-1.5) |
| Baseline Hb, g/L (median, IQR) | 148.5 (143.3-154.8) | 138.5 (128.5-144.0) |
| Baseline ferritin, ug/L (median, IQR) | 109.0 (38.0-157.0) | 83.50 (57.8-99.5) |
| Baseline eosinophil count, x109/L (median, IQR) | 0.2 (0.1-0.4) | 0.2 (0.1-0.4) |
| Characteristic . | Intervention (n = 10) . | Placebo (n = 10) . |
|---|---|---|
| Women,n(%) | 4 (40%) | 5 (50%) |
| Age, mean (SD) | 53.5 (9.3) | 48.0 (12.9) |
| Age category, n (%) | ||
| 18-30 | 0 (0) | 1 (10) |
| 30-50 | 3 (30) | 5 (50) |
| 50-70 | 7 (70) | 4 (40) |
| Smoking, n (%) | ||
| Current | 1 (10) | 1 (10) |
| Past | 5 (50) | 3 (30) |
| BMI (mean, SD) | 19.6 (7.0) | 26.4 (6.2) |
| Time since diagnosis, years (median, IQR) | 16 (2.8-20) | 16 (4.5-23.0) |
| Disease extent, n (%) | ||
| E1 | 1 (10) | 1 (10) |
| E2 | 8 (80) | 3 (30) |
| E3 | 1 (10) | 6 (60) |
| Disease severity at worst, n (%) | ||
| Mild | 1 (10) | 1 (10) |
| Mod | 9 (90) | 7 (70) |
| Severe | 0 (0) | 2 (20) |
| Previous IMM,n(%) | 2 (20) | 3 (30) |
| Previous biologic,n(%) | 0 (0) | 0 (0) |
| Steroid use in last year,n(%) | 1 (10) | 2 (20) |
| Previous steroid use,n(%) | 8 (80) | 6 (60) |
| Severity of inflammation at last endoscopy, n (%) | ||
| Nil | 2 (20) | 3 (30) |
| Mild | 2 (20) | 5 (50) |
| Mod | 6 (60) | 2 (20) |
| Severe | 0 (0) | 0 (0) |
| Baseline SCCAI score (median, IQR) | 2.0 (2.0-2.0) | 2.0 (2.0-2.0) |
| Baseline SIBDQ (median, IQR) | 59.0 (52.8-64.5) | 59.50 (55.8-64.0) |
| Baseline fCal, ug/g (median, IQR) | 32.0 (29.0-38.8) | 33.0 (28.8-64.8) |
| Baseline CRP, mg/L (median, IQR) | 1.0 (1.0-8.0) | 1.0 (1.0-1.5) |
| Baseline Hb, g/L (median, IQR) | 148.5 (143.3-154.8) | 138.5 (128.5-144.0) |
| Baseline ferritin, ug/L (median, IQR) | 109.0 (38.0-157.0) | 83.50 (57.8-99.5) |
| Baseline eosinophil count, x109/L (median, IQR) | 0.2 (0.1-0.4) | 0.2 (0.1-0.4) |
Abbreviations: BMI, body mass index; IMM, immunomodulator; SCCAI, simple clinical colitis activity index; SIBDQ, short inflammatory bowel disease questionnaire; fCal, fecal calprotectin; CRP, C-reactive protein; Hb, haemoglobin
Baseline demographic, disease and laboratory characteristics. Disease extent based on Montreal classification for ulcerative colitis.
| Characteristic . | Intervention (n = 10) . | Placebo (n = 10) . |
|---|---|---|
| Women,n(%) | 4 (40%) | 5 (50%) |
| Age, mean (SD) | 53.5 (9.3) | 48.0 (12.9) |
| Age category, n (%) | ||
| 18-30 | 0 (0) | 1 (10) |
| 30-50 | 3 (30) | 5 (50) |
| 50-70 | 7 (70) | 4 (40) |
| Smoking, n (%) | ||
| Current | 1 (10) | 1 (10) |
| Past | 5 (50) | 3 (30) |
| BMI (mean, SD) | 19.6 (7.0) | 26.4 (6.2) |
| Time since diagnosis, years (median, IQR) | 16 (2.8-20) | 16 (4.5-23.0) |
| Disease extent, n (%) | ||
| E1 | 1 (10) | 1 (10) |
| E2 | 8 (80) | 3 (30) |
| E3 | 1 (10) | 6 (60) |
| Disease severity at worst, n (%) | ||
| Mild | 1 (10) | 1 (10) |
| Mod | 9 (90) | 7 (70) |
| Severe | 0 (0) | 2 (20) |
| Previous IMM,n(%) | 2 (20) | 3 (30) |
| Previous biologic,n(%) | 0 (0) | 0 (0) |
| Steroid use in last year,n(%) | 1 (10) | 2 (20) |
| Previous steroid use,n(%) | 8 (80) | 6 (60) |
| Severity of inflammation at last endoscopy, n (%) | ||
| Nil | 2 (20) | 3 (30) |
| Mild | 2 (20) | 5 (50) |
| Mod | 6 (60) | 2 (20) |
| Severe | 0 (0) | 0 (0) |
| Baseline SCCAI score (median, IQR) | 2.0 (2.0-2.0) | 2.0 (2.0-2.0) |
| Baseline SIBDQ (median, IQR) | 59.0 (52.8-64.5) | 59.50 (55.8-64.0) |
| Baseline fCal, ug/g (median, IQR) | 32.0 (29.0-38.8) | 33.0 (28.8-64.8) |
| Baseline CRP, mg/L (median, IQR) | 1.0 (1.0-8.0) | 1.0 (1.0-1.5) |
| Baseline Hb, g/L (median, IQR) | 148.5 (143.3-154.8) | 138.5 (128.5-144.0) |
| Baseline ferritin, ug/L (median, IQR) | 109.0 (38.0-157.0) | 83.50 (57.8-99.5) |
| Baseline eosinophil count, x109/L (median, IQR) | 0.2 (0.1-0.4) | 0.2 (0.1-0.4) |
| Characteristic . | Intervention (n = 10) . | Placebo (n = 10) . |
|---|---|---|
| Women,n(%) | 4 (40%) | 5 (50%) |
| Age, mean (SD) | 53.5 (9.3) | 48.0 (12.9) |
| Age category, n (%) | ||
| 18-30 | 0 (0) | 1 (10) |
| 30-50 | 3 (30) | 5 (50) |
| 50-70 | 7 (70) | 4 (40) |
| Smoking, n (%) | ||
| Current | 1 (10) | 1 (10) |
| Past | 5 (50) | 3 (30) |
| BMI (mean, SD) | 19.6 (7.0) | 26.4 (6.2) |
| Time since diagnosis, years (median, IQR) | 16 (2.8-20) | 16 (4.5-23.0) |
| Disease extent, n (%) | ||
| E1 | 1 (10) | 1 (10) |
| E2 | 8 (80) | 3 (30) |
| E3 | 1 (10) | 6 (60) |
| Disease severity at worst, n (%) | ||
| Mild | 1 (10) | 1 (10) |
| Mod | 9 (90) | 7 (70) |
| Severe | 0 (0) | 2 (20) |
| Previous IMM,n(%) | 2 (20) | 3 (30) |
| Previous biologic,n(%) | 0 (0) | 0 (0) |
| Steroid use in last year,n(%) | 1 (10) | 2 (20) |
| Previous steroid use,n(%) | 8 (80) | 6 (60) |
| Severity of inflammation at last endoscopy, n (%) | ||
| Nil | 2 (20) | 3 (30) |
| Mild | 2 (20) | 5 (50) |
| Mod | 6 (60) | 2 (20) |
| Severe | 0 (0) | 0 (0) |
| Baseline SCCAI score (median, IQR) | 2.0 (2.0-2.0) | 2.0 (2.0-2.0) |
| Baseline SIBDQ (median, IQR) | 59.0 (52.8-64.5) | 59.50 (55.8-64.0) |
| Baseline fCal, ug/g (median, IQR) | 32.0 (29.0-38.8) | 33.0 (28.8-64.8) |
| Baseline CRP, mg/L (median, IQR) | 1.0 (1.0-8.0) | 1.0 (1.0-1.5) |
| Baseline Hb, g/L (median, IQR) | 148.5 (143.3-154.8) | 138.5 (128.5-144.0) |
| Baseline ferritin, ug/L (median, IQR) | 109.0 (38.0-157.0) | 83.50 (57.8-99.5) |
| Baseline eosinophil count, x109/L (median, IQR) | 0.2 (0.1-0.4) | 0.2 (0.1-0.4) |
Abbreviations: BMI, body mass index; IMM, immunomodulator; SCCAI, simple clinical colitis activity index; SIBDQ, short inflammatory bowel disease questionnaire; fCal, fecal calprotectin; CRP, C-reactive protein; Hb, haemoglobin
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
